UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Quiet quitting in nursing and healthcare professions

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Not sure what you can access? Learn more about account types.

Quiet quitting in nursing and healthcare professions

Gerlinde Weilguny-Schoefl 1

1 Allg. Krankenhaus Wien Abt. für Innere Medizin Abt. Endoskopie, Wien, Austria

Event

UEG Week Vienna 2024

Topics

Nurses

Session

Management: Increase staff wellbeing

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Image-guided surgery techniques

Mahdi Al-Taher 1

1 Maastricht UMC, Dubai, United Arab Emirates

Event

UEG Week Copenhagen 2023

Topics

Endoscopy Mechanisms & Personalised Medicine Radiology & Imaging Surgery

Session

Digestive diseases: Help from the machines?

Published

2023

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Is robotic resection better for cystic lesions?

Giuseppe Malleo 1

1 Unit of General and Pancreatic Surgery, University of Verona Hospital Trust, Verona, Italy

Event

UEG Week Berlin 2025

Topics

Digestive Oncology Gut Microbiota Pancreas

Session

Cystic neoplasms of the pancreas

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Upper gastrointestinal bleeding (UGIB) poses a significant threat in patients presenting to the emergency department, particularly in those with associated hemodynamic instability. Despite major advancements in medical and endoscopic therapeutic options, mortality rates have not shown a substantial decline over the years. This study aimed to assess clinical practice patterns in order to gain a clearer understanding of the pre-endoscopic assessment for patients with acute UGIB.

Aims & Methods

This study was an international online survey based on a prospective two-phase data collection approach, conducted between April 2023 and November 2023. The survey targeted practicing physicians actively involved in managing patients with UGIB. Data collection and management were performed through Research Electronic Data Capture (REDCap), an electronic data collection tool. The survey comprised four key domains: demographics and clinical practice, definitions of hemodynamic instability, pre-endoscopic assessment, and optimal timing of endoscopy, encompassing a total of 33 questions. The primary analysis provided a descriptive assessment of responses reported as proportions. Secondary analyses explored differences in responses based on years of clinical experience, practice setting, and the estimated annual number of UGIB cases encountered

Results

A total of 533 clinicians from 50 countries completed our survey. Among respondents, 54.6% work in university-based hospitals, and 67.7% reported managing over 100 UGIB patients annually. Regarding clinical experience, 55.7% have less than 10 years, with 44.3% with over 10 years of experience. Only 47.1% of respondents reported that their hospitals implement a triage system for UGIB patients. Additionally, 39.6% indicated that they do not use any risk stratification scores at the time of patient presentation. For initial fluid resuscitation, 0.9% saline (40.9%) and balanced crystalloid fluids (39.5%) were almost equally preferred. The rate of fluid resuscitation was reported to depend on the patient’s hemodynamic status by 40.2% of respondents. Most respondents indicated that hemodynamically unstable patients are primarily managed in the emergency department or intensive care unit. A total of 34.3% of respondents indicated that they do not routinely use prokinetics prior to endoscopy in UGIB patients, while 27.6% reported not commonly using them even in cases involving severe bleeding or known gastric emptying disorders. Proton pump inhibitors are administered prior to upper GI endoscopy in all cases by 70.4% of respondents, while vasoconstricting agents are used by 61% in cases of suspected variceal bleeding.

Conclusion

Our survey found considerable variability among respondents regarding the pre-endoscopic management of patients presenting with upper gastrointestinal hemorrhage. The overall adherence to international guidelines was low, which can potentially result in a significant negative impact on patient outcomes.

PRE-ENDOSCOPIC MANAGEMENT OF PATIENTS WITH UPPER GASTROINTESTINAL BLEEDING: RESULTS OF AN INTERNATIONAL SURVEY INCLUDING 533 CLINICIANS

Diana-Elena Floria 1, Mahmoud Obeidat 2, Brigitta Teutsch 3, Zsolt Abonyi-Tóth 4, Stig Borbjerg Laursen 5, Marine Camus 6, Franck Verdonk 7, Áron Vincze 8, Zsolt Bognár 9, Vasile Liviu Drug 10, Keith Siau 11, Ian Gralnek 12, Peter Hegyi 13, Balint Eross 14

1 Semmelweis University, Centre for Translational Medicine, Budapest, Hungary|||Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania

2 Semmelweis University, Centre for Translational Medicine, Budapest, Hungary|||Semmelweis University, Budapest, Hungary

3 Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary

4 Semmelweis University, Centre for Translational Medicine, Budapest, Hungary

5 Odense University Hospital, Odense, Denmark

6 Sorbonne University, Saint Antoine Hospital, Paris, France

7 Sorbonne University, Paris, France

8 University of Pécs, Pécs, Hungary

9 Heim Pal National Paediatric Institute, Budapest, Hungary

10 Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania

11 Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom

12 Emek Medical Center, Afula, Israel

13 Semmelweis University, Centre for Translational Medicine, Budapest, Hungary|||Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary

14 Semmelweis University, Budapest, Hungary|||Semmelweis University, Centre for Translational Medicine, Budapest, Hungary

Conference

UEG Week Berlin 2025

Topics

Oesophagus

Submission format

Abstract

Session

Upper GI bleeding (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

More or less chemoradiation for locallly advanced GEJ cancer?

Tamara Matysiak-Budnik 1

1 CHU de Nantes IMAD, Nantes, France

Event

UEG Week Copenhagen 2023

Topics

Digestive Oncology Oesophagus Stomach & H. Pylori Surgery

Session

Junctional gastro-oesophageal cancer

Published

2023

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). The recommended induction scheme is 10 mg twice daily (BID) for at least 8 weeks followed by a maintenance dose of 5 mg BID. However, some patients require 10mg bid, for 16 weeks at the induction phase. Our study aimed to assess the demographics and disease characteristics of such patients and their outcome at 24 weeks.

Aims & Methods

This was a multicenter, retrospective, observational study which included patients with moderate to severe UC, who received induction therapy with Tofacitinib 10mg bid for a 16-week period. Data were collected between July 2018 and November 2022. The primary objective was disease outcome, defined as clinical remission and/or the need of steroids. Secondary outcomes were treatment withdrawal, treatment de-escalation and adverse events.

Results

In total 31 patients, are currently enrolled in our study, from 10 IBD centres [males: 51.6%, mean age at study entry: 40.0 years, median disease duration: 7 years]. Patient demographic and clinical characteristics at baseline are shown in table 1. Four patients (12.9%) discontinued treatment before week 24, due to inadequate response. De-escalation of dosing to 5mg bid tofacitinib was attempted in 13 of 27 patients (48.1%) and was successful in 7 patients (53.8%) who maintained clinical response until week 24 of the study. Of the other 6 out of 13 patients, 6 patients received again the higher dose (10 mg bid) and regained response and only one patient discontinued treatment. Overall, 85.7% (6/7) of the patients who received tofacitinib 5mg bid and 66.7% (14/21) who received 10mg bid at 24 weeks, had received more than one biologic prior to tofacitinib (P=0.34). At week 24, the partial Mayo score was available in 26 patients; 13 patients were in steroid-free clinical remission (pMayo <2). Twelve patients had mild active disease (pMayo 2-4) and 9 of them had stopped steroids. No major adverse events were observed during the entire observation period.

Table 1. Demographic and clinical characteristics of patients (N=31)
Age [years; mean (±SD)]		41.0 (±13.6)
Sex [N (%)]	Male	16 (51.6)
BMI [kg/m²; median (IQR)]		26.8 (23.7 – 28.6)
Smokers [N (%)]	Never/Current/Prior	23 (74.2)/ 3 (9.7)/ 5 (16.1)
Previous treatment [N (%)]	Systemic corticosteroids	25 (80.6)
	Thiopurines/ Methotrexate	16 (51.6)/ 2 (6.5)
	Biologics	26 (83.9)
pMayo score [N (%)]	2-4/ 5-7/ >7	9 (29.0)/ 14 (45.2)/ 8 (25.8)
EndoMayo score [Ν (%)]	2/3	10 (32.3) / 18 (58.1)

Conclusion

In a real-world setting, a 24-week treatment with tofacitinib 10mg BID is safe and the majority of patients achieve clinical remission and manage to stop steroids. De-escalation at 5mg bid is successful in more than half of them. We prospectively follow up our cohort to investigate whether these preliminary results will be confirmed for a longer period.